Vizient Urges the Current Administration to Enable Federal Officials from Across the Government to Begin Formal Engagement with Biden’s Transition Team

November 20, 2020

Vizient, Inc., the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers, issued the following statement on the urgent need to allow the President-elect Biden’s transition team access to federal government efforts to combat the coronavirus:

Vizient believes the magnitude of the COVID-19 crisis requires a coordinated, wide-scale and continuous response from the federal government. We urge the current administration to enable federal officials from across the government to begin formal engagement with members of President-elect Biden’s transition team so that the ongoing response to combating the COVID-19 pandemic continues without interruption.”

Since the beginning of the pandemic, Vizient has worked closely with the current administration to help resolve supply chain issues and other challenges to support our member hospitals in their efforts to access essential medical supplies and equipment. It is important that steps the current administration has taken are seamlessly transitioned to the incoming administration’s plans. This transition is vital to meeting the needs of hospitals as they work to activate their COVID-19 case surge plans, procure essential medical supplies, and care for patients.

Of critical importance is information on the strategy to successfully launch a comprehensive and equitable vaccination distribution plan. Connecting current members of the administration with members of the incoming administration’s transition team would help guard against lapses in the national response moving forward. It would also help ensure that the current public/private partnership, that has been integral in the nation’s response thus far, can continue without interruption.

With so much hard work underway, and much that still needs to be done, Vizient urges the current administration to enable members of the President-elect Biden transition team to begin formal participation in the federal government’s COVID-19 planning.”

SourceVizient

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version